BRIEF-Affimed presents data from Phase 1B combination study of AFM13 with pembrolizumab at Ash By: Reuters: Company News December 11, 2017 at 05:46 AM EST * Affimed presents data from Phase 1B combination study of AFM13 with Pembrolizumab at Ash Read More >> Related Stocks: Affimed Ord Shs